Adenovirus vector-based vaccine for infectious diseases
Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transge...
Saved in:
| Published in | Drug metabolism and pharmacokinetics Vol. 42; p. 100432 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.02.2022
The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. |
|---|---|
| AbstractList | Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed.Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. |
| ArticleNumber | 100432 |
| Author | Tachibana, Masashi Sakurai, Fuminori Mizuguchi, Hiroyuki |
| Author_xml | – sequence: 1 givenname: Fuminori orcidid: 0000-0003-1366-9662 surname: Sakurai fullname: Sakurai, Fuminori email: sakurai@phs.osaka-u.ac.jp organization: Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan – sequence: 2 givenname: Masashi orcidid: 0000-0002-0376-508X surname: Tachibana fullname: Tachibana, Masashi organization: Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan – sequence: 3 givenname: Hiroyuki surname: Mizuguchi fullname: Mizuguchi, Hiroyuki email: mizuguch@phs.osaka-u.ac.jp organization: Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34974335$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UctqGzEUFSEh7x_oonjZzTh6SwOlEEKbBALZtGshS1eJ3LHkSuOB_H1l7Jq2i6z0OI8rnXOBjlNOgNAHgucEE3mznPvV-uecYkraBeaMHqFzojXucE_xcdszrjrOpDpDF7UuMWZMcHqKzhjvFW-Hc6RuPaQ8xbKpswncmEu3sBX8bLLOxQSzkMssptCgmBvHxwoNr1foJNihwvV-vUQ_vn39fvfQPT3fP97dPnVOUDJ2QlLmtATROyWZxz0QseixUs5xhUUIjDnFNfbKqt5qHcB7HbQmWCgOwbFL9GXnu94sVuAdpLHYwaxLXNnyZrKN5l8kxVfzkiejhRa9xM3g096g5F8bqKNZxepgGGyC9iFDJZFUaan6Rv3496zDkD9pNQLdEVzJtRYIBwrBZluJWZptJWZbidlV0kT6P5GLo21pbt8bh_eln3dSaAlPEYqpLkJy4GNphRif43vy310RpwY |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2024_07_019 crossref_primary_10_1002_jmv_70236 crossref_primary_10_3390_vaccines10111906 crossref_primary_10_3390_vaccines13030333 crossref_primary_10_1016_j_ijbiomac_2022_12_158 crossref_primary_10_1016_j_molmed_2022_10_009 crossref_primary_10_3390_v16030377 crossref_primary_10_3389_fpubh_2023_1326154 crossref_primary_10_1016_j_micpath_2025_107509 crossref_primary_10_1021_acsinfecdis_4c00619 crossref_primary_10_1248_yakushi_24_00177_1 crossref_primary_10_7759_cureus_50703 crossref_primary_10_1016_j_molmed_2022_10_001 crossref_primary_10_3390_microbiolres15030105 crossref_primary_10_3390_genes13112129 crossref_primary_10_3390_vaccines12020191 crossref_primary_10_3390_vaccines12050459 crossref_primary_10_3389_fimmu_2023_1183258 crossref_primary_10_1007_s12033_022_00616_8 crossref_primary_10_3389_fcimb_2022_887729 crossref_primary_10_1080_21645515_2025_2450120 crossref_primary_10_1093_trstmh_trae082 crossref_primary_10_1016_j_ymthe_2022_02_016 crossref_primary_10_3389_fimmu_2023_1126034 crossref_primary_10_1016_j_intimp_2025_114032 crossref_primary_10_3390_microorganisms11020302 crossref_primary_10_3390_v15122378 crossref_primary_10_3389_fimmu_2024_1374486 crossref_primary_10_1002_biot_202300658 crossref_primary_10_3390_genes13111941 crossref_primary_10_1080_21645515_2022_2052525 crossref_primary_10_3390_biology13121052 crossref_primary_10_3390_v16010052 crossref_primary_10_1002_jgm_3576 crossref_primary_10_1016_j_ymthe_2024_05_036 crossref_primary_10_1111_irv_13233 crossref_primary_10_1016_j_omtm_2024_101356 crossref_primary_10_1080_22221751_2023_2290838 crossref_primary_10_1016_j_btre_2023_e00803 crossref_primary_10_1016_j_trim_2023_101804 crossref_primary_10_1021_acsnano_4c13146 crossref_primary_10_1080_14760584_2023_2242528 crossref_primary_10_3390_v16050761 crossref_primary_10_3390_vaccines11071232 crossref_primary_10_4103_2773_0344_387693 crossref_primary_10_1016_j_vaccine_2022_02_019 crossref_primary_10_12677_ACM_2023_134843 crossref_primary_10_1038_s41541_022_00567_w crossref_primary_10_3390_pharmaceutics14101983 crossref_primary_10_1248_bpb_b23_00837 crossref_primary_10_1038_s41392_023_01408_5 crossref_primary_10_5694_mja2_51620 crossref_primary_10_1016_j_engmic_2024_100162 crossref_primary_10_1016_j_actbio_2024_04_010 crossref_primary_10_3390_ijms26030921 crossref_primary_10_3390_v17030414 crossref_primary_10_1016_j_tim_2023_09_002 crossref_primary_10_3390_vaccines11030573 crossref_primary_10_3389_av_2023_11642 crossref_primary_10_3389_fcimb_2024_1336013 crossref_primary_10_2174_1568026623666230825094341 crossref_primary_10_1016_j_ijpharm_2024_124480 crossref_primary_10_3390_jcm13010087 crossref_primary_10_3390_vaccines12050552 crossref_primary_10_18231_j_ijcaap_2024_003 crossref_primary_10_3390_v14112400 crossref_primary_10_3390_cells12131762 crossref_primary_10_1016_j_jcjp_2024_100186 crossref_primary_10_3389_fimmu_2023_1141794 crossref_primary_10_3389_fimmu_2023_1238882 crossref_primary_10_15789_1563_0625_AOM_2630 crossref_primary_10_3390_v14050959 crossref_primary_10_3390_vaccines12111247 crossref_primary_10_3389_fimmu_2023_1220610 crossref_primary_10_1007_s11739_022_03112_8 crossref_primary_10_37285_ijpsn_2023_16_4_8 crossref_primary_10_3390_genes15040467 crossref_primary_10_3390_v16071094 crossref_primary_10_1016_j_biomaterials_2024_122853 crossref_primary_10_1038_s41598_023_40103_x crossref_primary_10_1186_s13568_022_01398_7 |
| Cites_doi | 10.1016/S0140-6736(08)61591-3 10.1038/s41586-020-2607-z 10.1038/nature12306 10.1038/nature04721 10.1016/j.ymthe.2021.05.015 10.1126/science.aax8819 10.1016/S2352-3018(20)30229-0 10.1016/S0140-6736(08)61592-5 10.1038/nm.3702 10.1038/s41423-020-00602-7 10.3389/fimmu.2017.01456 10.1016/j.vaccine.2020.08.050 10.1006/mthe.2002.0545 10.1016/S0140-6736(20)31605-6 10.1016/S0140-6736(21)00628-0 10.1002/1873-3468.13696 10.7326/M20-5306 10.1016/S0140-6736(20)31866-3 10.1038/sj.gt.3301959 10.1128/jvi.70.10.6839-6846.1996 10.1016/0092-8674(93)90231-E 10.1128/JVI.78.23.13207-13215.2004 10.1128/IAI.74.1.313-320.2006 10.1128/JVI.02696-06 10.1089/hum.2007.040 10.1016/j.virol.2009.09.018 10.1016/j.vaccine.2004.07.043 10.1016/S1368-8375(03)00047-2 10.1074/jbc.274.15.10219 10.1128/CVI.00010-12 10.4049/jimmunol.181.3.2134 10.1016/j.biomaterials.2010.10.060 10.1038/nm.2270 10.1038/nature06664 10.1080/22221751.2020.1719902 10.1089/hum.2007.016 10.1128/JVI.72.8.6875-6879.1998 10.1128/JVI.75.23.11603-11613.2001 10.1128/JVI.74.6.2567-2583.2000 10.3389/fimmu.2018.00124 10.4049/jimmunol.1700698 10.1182/bloodadvances.2021004904 10.1016/S0140-6736(77)92000-1 10.1002/jgm.1530 10.1002/jgm.964 10.1097/COH.0b013e32833d2d2b 10.1128/JVI.74.1.42-48.2000 10.3389/fbioe.2020.574007 10.1128/JVI.01722-17 10.1056/NEJMoa2104840 10.1073/pnas.261452898 10.1128/JVI.77.17.9183-9191.2003 10.1016/S0140-6736(16)00080-5 10.1016/S1525-0016(03)00243-0 10.1128/JVI.00866-09 10.1099/vir.0.000196 10.1016/j.jaut.2021.102681 10.1016/j.bbrc.2012.07.056 10.1073/pnas.1009823107 10.1016/j.virusres.2019.05.008 10.1126/science.275.5304.1320 10.4049/jimmunol.181.6.4188 10.3855/jidc.6197 10.1128/JVI.00821-09 10.1093/emboj/16.19.5998 10.1016/S0140-6736(15)60553-0 10.1056/NEJMoa2101544 10.1021/mp900151k 10.1016/S0140-6736(20)31208-3 10.1128/JVI.00500-16 10.1073/pnas.1014074107 10.1016/j.biomaterials.2016.02.025 10.1128/JVI.01597-10 10.1074/jbc.272.33.20793 10.1089/10430349950018021 10.1089/10430349950018409 10.1093/milmed/160.6.300 10.1016/j.cell.2008.01.016 10.1126/sciadv.aax3567 10.3389/fimmu.2021.685218 10.1371/journal.pone.0040385 10.1371/journal.pone.0101591 10.1128/JVI.00450-10 10.1016/S0140-6736(21)00234-8 10.1016/j.ebiom.2018.02.011 10.1038/nm952 10.1093/infdis/jiy187 10.4049/jimmunol.174.11.7179 10.1038/sj.mt.6300031 10.1093/infdis/jiu485 10.1016/j.celrep.2021.109400 10.1089/hum.1997.8.17-2103 10.1016/j.biomaterials.2012.02.011 10.1099/vir.0.82079-0 10.1099/vir.0.81293-0 10.1128/JVI.02160-10 10.1172/JCI78280 10.1128/JVI.02563-09 10.1128/JVI.79.8.5090-5104.2005 |
| ContentType | Journal Article |
| Copyright | 2021 The Japanese Society for the Study of Xenobiotics Copyright © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. 2021 The Japanese Society for the Study of Xenobiotics |
| Copyright_xml | – notice: 2021 The Japanese Society for the Study of Xenobiotics – notice: Copyright © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. – notice: 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. 2021 The Japanese Society for the Study of Xenobiotics |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.dmpk.2021.100432 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1880-0920 |
| EndPage | 100432 |
| ExternalDocumentID | PMC8585960 34974335 10_1016_j_dmpk_2021_100432 S1347436721000537 |
| Genre | Journal Article Review |
| GroupedDBID | --- --M 0R~ 29G 2WC 4.4 457 53G 5GY 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABJNI ABMAC ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE AEBSH AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BAWUL BKOJK BKOMP BLXMC CS3 DIK DU5 E3Z EBS EFJIC EFLBG EJD F5P FDB FEDTE FIRID FYGXN GBLVA GX1 HH5 HVGLF HZ~ JMI JSF JSH KOM KQ8 M41 MOJWN M~E O9- OAUVE RJT RNS ROL RZJ SPCBC SSP SSZ T5K TKC TR2 ~G- AAQFI AATTM AAXKI AAYWO AAYXX ACVFH ADCNI AEIPS AEUPX AFJKZ AFPUW AGCQF AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION OVT SSH CGR CUY CVF ECM EIF NPM 7X8 EFKBS 5PM |
| ID | FETCH-LOGICAL-c521t-5623c86e59c763d09e15b9077cc4705ff33c7480d7a79a88fedd8f8810574efc3 |
| IEDL.DBID | AIKHN |
| ISSN | 1347-4367 1880-0920 |
| IngestDate | Thu Aug 21 13:48:32 EDT 2025 Mon Jul 21 10:09:20 EDT 2025 Wed Feb 19 02:08:35 EST 2025 Tue Jul 01 03:08:32 EDT 2025 Thu Apr 24 23:01:46 EDT 2025 Fri Feb 23 02:40:25 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Innate immunity Vaccine Infectious diseases Adenovirus vector Pre-existing antibody |
| Language | English |
| License | Copyright © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-5623c86e59c763d09e15b9077cc4705ff33c7480d7a79a88fedd8f8810574efc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-0376-508X 0000-0003-1366-9662 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8585960 |
| PMID | 34974335 |
| PQID | 2616278679 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8585960 proquest_miscellaneous_2616278679 pubmed_primary_34974335 crossref_primary_10_1016_j_dmpk_2021_100432 crossref_citationtrail_10_1016_j_dmpk_2021_100432 elsevier_sciencedirect_doi_10_1016_j_dmpk_2021_100432 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Drug metabolism and pharmacokinetics |
| PublicationTitleAlternate | Drug Metab Pharmacokinet |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd |
| References | Stanley, Honko, Asiedu, Trefry, Lau-Kilby, Johnson (bib93) 2014; 20 Minamitani, Iwakiri, Takada (bib36) 2011; 85 van Doremalen, Lambe, Spencer, Belij-Rammerstorfer, Purushotham, Port (bib103) 2020 Greinacher, Thiele, Warkentin, Weisser, Kyrle, Eichinger (bib101) 2021; 384 Volkmann, Williamson, Weidenthaler, Meyer, Robertson, Excler (bib92) 2021; 39 Buchbinder, Mehrotra, Duerr, Fitzgerald, Mogg, Li (bib76) 2008; 372 Bergelson, Cunningham, Droguett, Kurt-Jones, Krithivas, Hong (bib2) 1997; 275 Roberts, Nanda, Havenga, Abbink, Lynch, Ewald (bib60) 2006; 441 Roy, Shirley, McClelland, Kaleko (bib58) 1998; 72 Chéneau, Eichholz, Tran, Tran, Paris, Henriquet (bib30) 2021; 12 Yotnda, Chen, Chiu, Piedra, Davis, Templeton (bib71) 2002; 5 Logunov, Dolzhikova, Zubkova, Tukhvatulin, Shcheblyakov, Dzharullaeva (bib105) 2020; 396 Zhu, Li, Guan, Hou, Wang, Li (bib106) 2020; 395 Bogoch, Brady, Kraemer, German, Creatore, Kulkarni (bib81) 2016; 387 Segerman, Atkinson, Marttila, Dennerquist, Wadell, Arnberg (bib9) 2003; 77 Walters, Grunst, Bergelson, Finberg, Welsh, Zabner (bib22) 1999; 274 Kaufman, Bivas-Benita, Simmons, Miller, Barouch (bib47) 2010; 84 Baker, Mundy, Davies, Rizkallah, Parker (bib12) 2019; 5 Cerullo, Seiler, Mane, Brunetti-Pierri, Clarke, Bertin (bib26) 2007; 15 Cheng, Gall, Nason, King, Koup, Roederer (bib59) 2010; 84 Logunov, Dolzhikova, Shcheblyakov, Tukhvatulin, Zubkova, Dzharullaeva (bib97) 2021; 397 Sadoff, Gray, Vandebosch, Cárdenas, Shukarev, Grinsztejn (bib98) 2021; 384 Xu, Song, Dai, Zhang, Lu, Xie (bib82) 2018; 92 Quinn, Zak, Costa, Yamamoto, Kastenmuller, Hill (bib45) 2015; 125 Rhee, Blattman, Kasturi, Kelley, Kaufman, Lynch (bib31) 2011; 85 Sakurai, Mizuguchi, Yamaguchi, Hayakawa (bib7) 2003; 8 Luo, Zhang, Ma, Wang, Lu, Liu (bib66) 2019; 268 Stone, Ni, Li, Gaggar, DiPaolo, Feng (bib16) 2005; 79 (bib85) 2020; 62 Zhu, Hou, Li, Wu, Liu, Zhang (bib94) 2015; 385 Nwanegbo, Vardas, Gao, Whittle, Sun, Rowe (bib53) 2004; 11 Maisner, Zimmer, Liszewski, Lublin, Atkinson, Herrler (bib23) 1997; 272 Suzuki-Kouyama, Katayama, Sakurai, Yamaguchi, Kurachi, Kawabata (bib68) 2011; 32 Salisch, Stephenson, Williams, Cox, van der Fits, Heerwegh (bib84) 2021; 174 Chan, Kok, Zhu, Chu, To, Yuan (bib95) 2020; 9 Coughlan, Sridhar, Payne, Edmans, Milicic, Venkatraman (bib86) 2018; 29 Bricker, Darling, Hassan, Harastani, Soung, Jiang (bib43) 2021; 36 Gaydos, Gaydos (bib89) 1995; 160 Kaufman, Liu, Carville, Mansfield, Havenga, Goudsmit (bib50) 2008; 181 Krasnykh, Mikheeva, Douglas, Curiel (bib15) 1996; 70 Patterson, Kuate, Daltabuit-Test, Li, Xiao, McKinnon (bib44) 2012; 19 Klonjkowski, Gilardi-Hebenstreit, Hadchouel, Randrianarison, Boutin, Yeh (bib63) 1997; 8 Zhong, Shi, Han, Zhang, Sun (bib72) 2010; 7 Liu, Niu, Fan, Liu, Zhang, Wei (bib39) 2017; 199 Van Kampen, Shi, Gao, Zhang, Foster, Chen (bib87) 2005; 23 Mercado, Zahn, Wegmann, Loos, Chandrashekar, Yu (bib104) 2020; 586 Roy, Medina-Jaszek, Wilson, Sandhu, Calcedo, Lin (bib62) 2011; 13 Wang, Li, Liu, Persson, Beyer, Möller (bib10) 2011; 17 Baden, Stieh, Sarnecki, Walsh, Tomaras, Kublin (bib79) 2020; 7 Abbink, Lemckert, Ewald, Lynch, Denholtz, Smits (bib54) 2007; 81 Provine, Amini, Garner, Spencer, Dold, Hutchings (bib46) 2021; 371 Sumida, Truitt, Lemckert, Vogels, Custers, Addo (bib52) 2005; 174 Zhang, Wu, Zhang, Wei, Wu (bib75) 2020; 8 Onomoto, Onoguchi, Yoneyama (bib34) 2021; 18 Gaggar, Shayakhmetov, Lieber (bib8) 2003; 9 Johnson, Lange, Webb, Murphy (bib91) 1977; 1 Arnberg, Edlund, Kidd, Wadell (bib11) 2000; 74 Zhuang, Lai, Sun, Chen, Zhang, Dai (bib48) 2021 Appledorn, Patial, Godbehere, Parameswaran, Amalfitano (bib29) 2009; 1 Basner-Tschakarjan, Gaffal, O'Keeffe, Tormo, Limmer, Wagner (bib25) 2006; 8 Yamaguchi, Kawabata, Koizumi, Sakurai, Nakashima, Sakurai (bib27) 2007; 18 Sakurai, Mizuguchi, Hayakawa (bib14) 2003; 10 Holterman, Vogels, van der Vlugt, Sieuwerts, Grimbergen, Kaspers (bib51) 2004; 78 Ophorst, Radosević, Havenga, Pau, Holterman, Berkhout (bib57) 2006; 74 McElrath, De Rosa, Moodie, Dubey, Kierstead, Janes (bib77) 2008; 372 Farina, Gao, Xiang, Rux, Burnett, Alvira (bib64) 2001; 75 Tølbøll Sørensen, Rolland, Hartmann, Harboe, Roed, Jensen (bib100) 2021; 5 Muruve, Pétrilli, Zaiss, White, Clark, Ross (bib40) 2008; 452 Nalbantoglu, Pari, Karpati, Holland (bib18) 1999; 10 Park, Lee, Ahn, Byun, Seong, Baek (bib42) 2009; 395 Ablasser, Goldeck, Cavlar, Deimling, Witte, Röhl (bib32) 2013; 498 Anchim, Raddi, Zig, Perrieau, Le Goffic, Ryffel (bib38) 2018; 9 Yamaguchi, Kawabata, Kouyama, Ishii, Katayama, Suzuki (bib35) 2010; 107 Kakiuchi, Kuroda, Kanaya, Kumon, Tsumura, Hashimoto (bib74) 2021 Matsuda, Migueles, Huang, Bolkhovitinov, Stuccio, Griesman (bib88) 2021 Shayakhmetov, Papayannopoulou, Stamatoyannopoulos, Lieber (bib13) 2000; 74 Guo, Chan, Poon, Wu, Chan, Hou (bib83) 2018; 218 Verhaagh, de Jong, Goudsmit, Lecollinet, Gillissen, de Vries (bib21) 2006; 87 Johnstone, Loveland, McKenzie (bib20) 1993; 79 Fukuhara, Hayashi, Yamamoto, Fukui, Nishikawa, Mitsudo (bib70) 2003; 39 Zhu, Guan, Li, Huang, Jiang, Hou (bib99) 2020; 396 Barouch, Liu, Lynch, O'Brien, La Porte, Simmons (bib61) 2009; 83 Emary, Golubchik, Aley, Ariani, Angus, Bibi (bib96) 2021; 397 Greber, Suomalainen, Stidwill, Boucke, Ebersold, Helenius (bib5) 1997; 16 Chen, Xiang, Li, Kurupati, Jia, Bian (bib17) 2010; 84 Baden, Liu, Li, Johnson, Walsh, Kleinjan (bib41) 2015; 211 Appledorn, Patial, McBride, Godbehere, Van Rooijen, Parameswaran (bib28) 2008; 181 Atasheva, Yao, Shayakhmetov (bib24) 2019; 593 Wickham, Mathias, Cheresh, Nemerow (bib4) 1993; 73 Waddington, McVey, Bhella, Parker, Barker, Atoda (bib6) 2008; 132 Lemckert, Grimbergen, Smits, Hartkoorn, Holterman, Berkhout (bib55) 2006; 87 Hwang, Lee, Lee, Lee, Koyanagi, Jacob (bib102) 2021; 122 Shoji, Tachibana, Katayama, Tomita, Tsuzuki, Sakurai (bib37) 2012; 425 Matsui, Sakurai, Katayama, Yamaguchi, Okamoto, Takahira (bib67) 2012; 33 Hage, Gerd Liebert, Bergs, Ganzenmueller, Heim (bib1) 2015; 96 Dhama, Malik, Malik, Singh (bib90) 2015; 9 Dicks, Spencer, Edwards, Wadell, Bojang, Gilbert (bib65) 2012; 7 Gray, Buchbinder, Duerr (bib78) 2010; 5 Anghelina, Lam, Falck-Pedersen (bib33) 2016; 90 O'Riordan, Lachapelle, Delgado, Parkes, Wadsworth, Smith (bib69) 1999; 10 Hayton, Rose, Ibrahimsa, Del Sorbo, Capone, Crook (bib80) 2014; 9 Cohen, Shieh, Pickles, Okegawa, Hsieh, Bergelson (bib3) 2001; 98 Hemmi, Tachibana, Fujimoto, Shoji, Sakurai, Kobiyama (bib49) 2017; 8 Larochelle, Deol, Srivastava, Allen, Mizuguchi, Karpati (bib19) 2008; 19 Mallery, McEwan, Bidgood, Towers, Johnson, James (bib56) 2010; 107 Ran, Tan, Li, Zhang, Ma, Ji (bib73) 2016; 89 (10.1016/j.dmpk.2021.100432_bib85) 2020; 62 Quinn (10.1016/j.dmpk.2021.100432_bib45) 2015; 125 Larochelle (10.1016/j.dmpk.2021.100432_bib19) 2008; 19 Appledorn (10.1016/j.dmpk.2021.100432_bib29) 2009; 1 Kakiuchi (10.1016/j.dmpk.2021.100432_bib74) 2021 Johnson (10.1016/j.dmpk.2021.100432_bib91) 1977; 1 Hage (10.1016/j.dmpk.2021.100432_bib1) 2015; 96 Ran (10.1016/j.dmpk.2021.100432_bib73) 2016; 89 Roy (10.1016/j.dmpk.2021.100432_bib58) 1998; 72 Tølbøll Sørensen (10.1016/j.dmpk.2021.100432_bib100) 2021; 5 Logunov (10.1016/j.dmpk.2021.100432_bib97) 2021; 397 Roy (10.1016/j.dmpk.2021.100432_bib62) 2011; 13 Cohen (10.1016/j.dmpk.2021.100432_bib3) 2001; 98 Lemckert (10.1016/j.dmpk.2021.100432_bib55) 2006; 87 Segerman (10.1016/j.dmpk.2021.100432_bib9) 2003; 77 Guo (10.1016/j.dmpk.2021.100432_bib83) 2018; 218 Coughlan (10.1016/j.dmpk.2021.100432_bib86) 2018; 29 Bergelson (10.1016/j.dmpk.2021.100432_bib2) 1997; 275 Nwanegbo (10.1016/j.dmpk.2021.100432_bib53) 2004; 11 Ophorst (10.1016/j.dmpk.2021.100432_bib57) 2006; 74 Sakurai (10.1016/j.dmpk.2021.100432_bib7) 2003; 8 Maisner (10.1016/j.dmpk.2021.100432_bib23) 1997; 272 Hwang (10.1016/j.dmpk.2021.100432_bib102) 2021; 122 Zhuang (10.1016/j.dmpk.2021.100432_bib48) 2021 Verhaagh (10.1016/j.dmpk.2021.100432_bib21) 2006; 87 Holterman (10.1016/j.dmpk.2021.100432_bib51) 2004; 78 Onomoto (10.1016/j.dmpk.2021.100432_bib34) 2021; 18 Stanley (10.1016/j.dmpk.2021.100432_bib93) 2014; 20 Yamaguchi (10.1016/j.dmpk.2021.100432_bib27) 2007; 18 Park (10.1016/j.dmpk.2021.100432_bib42) 2009; 395 Krasnykh (10.1016/j.dmpk.2021.100432_bib15) 1996; 70 Sumida (10.1016/j.dmpk.2021.100432_bib52) 2005; 174 Fukuhara (10.1016/j.dmpk.2021.100432_bib70) 2003; 39 Volkmann (10.1016/j.dmpk.2021.100432_bib92) 2021; 39 Zhong (10.1016/j.dmpk.2021.100432_bib72) 2010; 7 Wickham (10.1016/j.dmpk.2021.100432_bib4) 1993; 73 Sakurai (10.1016/j.dmpk.2021.100432_bib14) 2003; 10 Suzuki-Kouyama (10.1016/j.dmpk.2021.100432_bib68) 2011; 32 Rhee (10.1016/j.dmpk.2021.100432_bib31) 2011; 85 Shayakhmetov (10.1016/j.dmpk.2021.100432_bib13) 2000; 74 Ablasser (10.1016/j.dmpk.2021.100432_bib32) 2013; 498 Anchim (10.1016/j.dmpk.2021.100432_bib38) 2018; 9 Hayton (10.1016/j.dmpk.2021.100432_bib80) 2014; 9 Nalbantoglu (10.1016/j.dmpk.2021.100432_bib18) 1999; 10 Mallery (10.1016/j.dmpk.2021.100432_bib56) 2010; 107 Gaggar (10.1016/j.dmpk.2021.100432_bib8) 2003; 9 Greinacher (10.1016/j.dmpk.2021.100432_bib101) 2021; 384 Patterson (10.1016/j.dmpk.2021.100432_bib44) 2012; 19 Baker (10.1016/j.dmpk.2021.100432_bib12) 2019; 5 Walters (10.1016/j.dmpk.2021.100432_bib22) 1999; 274 Gaydos (10.1016/j.dmpk.2021.100432_bib89) 1995; 160 Arnberg (10.1016/j.dmpk.2021.100432_bib11) 2000; 74 Chan (10.1016/j.dmpk.2021.100432_bib95) 2020; 9 Emary (10.1016/j.dmpk.2021.100432_bib96) 2021; 397 Van Kampen (10.1016/j.dmpk.2021.100432_bib87) 2005; 23 Cerullo (10.1016/j.dmpk.2021.100432_bib26) 2007; 15 Bricker (10.1016/j.dmpk.2021.100432_bib43) 2021; 36 Johnstone (10.1016/j.dmpk.2021.100432_bib20) 1993; 79 McElrath (10.1016/j.dmpk.2021.100432_bib77) 2008; 372 Roberts (10.1016/j.dmpk.2021.100432_bib60) 2006; 441 Abbink (10.1016/j.dmpk.2021.100432_bib54) 2007; 81 Chéneau (10.1016/j.dmpk.2021.100432_bib30) 2021; 12 Anghelina (10.1016/j.dmpk.2021.100432_bib33) 2016; 90 Stone (10.1016/j.dmpk.2021.100432_bib16) 2005; 79 Minamitani (10.1016/j.dmpk.2021.100432_bib36) 2011; 85 Waddington (10.1016/j.dmpk.2021.100432_bib6) 2008; 132 Kaufman (10.1016/j.dmpk.2021.100432_bib47) 2010; 84 Bogoch (10.1016/j.dmpk.2021.100432_bib81) 2016; 387 Buchbinder (10.1016/j.dmpk.2021.100432_bib76) 2008; 372 Appledorn (10.1016/j.dmpk.2021.100432_bib28) 2008; 181 Wang (10.1016/j.dmpk.2021.100432_bib10) 2011; 17 Baden (10.1016/j.dmpk.2021.100432_bib79) 2020; 7 Salisch (10.1016/j.dmpk.2021.100432_bib84) 2021; 174 Yamaguchi (10.1016/j.dmpk.2021.100432_bib35) 2010; 107 Atasheva (10.1016/j.dmpk.2021.100432_bib24) 2019; 593 Barouch (10.1016/j.dmpk.2021.100432_bib61) 2009; 83 Mercado (10.1016/j.dmpk.2021.100432_bib104) 2020; 586 Logunov (10.1016/j.dmpk.2021.100432_bib105) 2020; 396 Greber (10.1016/j.dmpk.2021.100432_bib5) 1997; 16 Farina (10.1016/j.dmpk.2021.100432_bib64) 2001; 75 Dhama (10.1016/j.dmpk.2021.100432_bib90) 2015; 9 Provine (10.1016/j.dmpk.2021.100432_bib46) 2021; 371 Basner-Tschakarjan (10.1016/j.dmpk.2021.100432_bib25) 2006; 8 Sadoff (10.1016/j.dmpk.2021.100432_bib98) 2021; 384 Shoji (10.1016/j.dmpk.2021.100432_bib37) 2012; 425 Baden (10.1016/j.dmpk.2021.100432_bib41) 2015; 211 Klonjkowski (10.1016/j.dmpk.2021.100432_bib63) 1997; 8 Yotnda (10.1016/j.dmpk.2021.100432_bib71) 2002; 5 Xu (10.1016/j.dmpk.2021.100432_bib82) 2018; 92 Zhu (10.1016/j.dmpk.2021.100432_bib106) 2020; 395 O'Riordan (10.1016/j.dmpk.2021.100432_bib69) 1999; 10 Muruve (10.1016/j.dmpk.2021.100432_bib40) 2008; 452 Kaufman (10.1016/j.dmpk.2021.100432_bib50) 2008; 181 Zhang (10.1016/j.dmpk.2021.100432_bib75) 2020; 8 Dicks (10.1016/j.dmpk.2021.100432_bib65) 2012; 7 Hemmi (10.1016/j.dmpk.2021.100432_bib49) 2017; 8 Matsuda (10.1016/j.dmpk.2021.100432_bib88) 2021 Luo (10.1016/j.dmpk.2021.100432_bib66) 2019; 268 Gray (10.1016/j.dmpk.2021.100432_bib78) 2010; 5 Zhu (10.1016/j.dmpk.2021.100432_bib99) 2020; 396 Liu (10.1016/j.dmpk.2021.100432_bib39) 2017; 199 Cheng (10.1016/j.dmpk.2021.100432_bib59) 2010; 84 Matsui (10.1016/j.dmpk.2021.100432_bib67) 2012; 33 Zhu (10.1016/j.dmpk.2021.100432_bib94) 2015; 385 van Doremalen (10.1016/j.dmpk.2021.100432_bib103) 2020 Chen (10.1016/j.dmpk.2021.100432_bib17) 2010; 84 |
| References_xml | – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: bib98 article-title: Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19 publication-title: N Engl J Med – volume: 5 start-page: eaax3567 year: 2019 ident: bib12 article-title: Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor publication-title: Sci Adv – volume: 79 start-page: 5090 year: 2005 end-page: 5104 ident: bib16 article-title: Development and assessment of human adenovirus type 11 as a gene transfer vector publication-title: J Virol – volume: 107 start-page: 19985 year: 2010 end-page: 19990 ident: bib56 article-title: Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) publication-title: Proc Natl Acad Sci U S A – volume: 92 year: 2018 ident: bib82 article-title: Recombinant chimpanzee adenovirus vaccine AdC7-M/E protects against Zika virus infection and testis damage publication-title: J Virol – volume: 593 start-page: 3461 year: 2019 end-page: 3483 ident: bib24 article-title: Innate immunity to adenovirus: lessons from mice publication-title: FEBS Lett – volume: 11 start-page: 351 year: 2004 end-page: 357 ident: bib53 article-title: Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States publication-title: Clin Diagn Lab Immunol – volume: 441 start-page: 239 year: 2006 end-page: 243 ident: bib60 article-title: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity publication-title: Nature – volume: 9 year: 2014 ident: bib80 article-title: Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial publication-title: PLoS One – volume: 372 start-page: 1894 year: 2008 end-page: 1905 ident: bib77 article-title: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis publication-title: Lancet (Lond. Engl.) – volume: 7 start-page: 105 year: 2010 end-page: 115 ident: bib72 article-title: Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells publication-title: Mol Pharm – volume: 10 start-page: 1009 year: 1999 end-page: 1019 ident: bib18 article-title: Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells publication-title: Hum Gene Ther – volume: 10 start-page: 1041 year: 2003 end-page: 1048 ident: bib14 article-title: Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector publication-title: Gene Ther – volume: 107 start-page: 17286 year: 2010 end-page: 17291 ident: bib35 article-title: Induction of type I interferon by adenovirus-encoded small RNAs publication-title: Proc Natl Acad Sci U S A – volume: 498 start-page: 380 year: 2013 end-page: 384 ident: bib32 article-title: cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING publication-title: Nature – volume: 32 start-page: 1724 year: 2011 end-page: 1730 ident: bib68 article-title: Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction publication-title: Biomaterials – volume: 274 start-page: 10219 year: 1999 end-page: 10226 ident: bib22 article-title: Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia publication-title: J Biol Chem – volume: 218 start-page: 365 year: 2018 end-page: 377 ident: bib83 article-title: Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models publication-title: J Infect Dis – volume: 74 start-page: 2567 year: 2000 end-page: 2583 ident: bib13 article-title: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector publication-title: J Virol – volume: 397 start-page: 1351 year: 2021 end-page: 1362 ident: bib96 article-title: Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial publication-title: Lancet (Lond. Engl.) – volume: 1 start-page: 376 year: 2009 end-page: 388 ident: bib29 article-title: TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses publication-title: J Innate Immun – volume: 62 start-page: 145 year: 2020 end-page: 150 ident: bib85 article-title: Influenza vaccine for 2020-2021 publication-title: Med Lett Drugs Ther – volume: 8 start-page: 2103 year: 1997 end-page: 2115 ident: bib63 article-title: A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo publication-title: Hum Gene Ther – volume: 371 start-page: 521 year: 2021 end-page: 526 ident: bib46 article-title: MAIT cell activation augments adenovirus vector vaccine immunogenicity publication-title: Science – volume: 15 start-page: 378 year: 2007 end-page: 385 ident: bib26 article-title: Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors publication-title: Mol Ther – volume: 387 start-page: 335 year: 2016 end-page: 336 ident: bib81 article-title: Anticipating the international spread of Zika virus from Brazil publication-title: Lancet (Lond. Engl.) – volume: 12 year: 2021 ident: bib30 article-title: Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes publication-title: Front Immunol – volume: 181 start-page: 2134 year: 2008 end-page: 2144 ident: bib28 article-title: Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo publication-title: J Immunol – volume: 33 start-page: 3743 year: 2012 end-page: 3755 ident: bib67 article-title: A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X publication-title: Biomaterials – volume: 174 start-page: 585 year: 2021 end-page: 594 ident: bib84 article-title: A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an ad26-vectored anti-zika virus vaccine publication-title: Ann Intern Med – volume: 8 year: 2020 ident: bib75 article-title: Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor publication-title: Front Bioeng Biotechnol – volume: 5 start-page: 2569 year: 2021 end-page: 2574 ident: bib100 article-title: A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 publication-title: Blood Adv – volume: 16 start-page: 5998 year: 1997 end-page: 6007 ident: bib5 article-title: The role of the nuclear pore complex in adenovirus DNA entry publication-title: EMBO J – volume: 272 start-page: 20793 year: 1997 end-page: 20799 ident: bib23 article-title: Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed. Importance of the tetrapeptide FTSL at the carboxyl terminus publication-title: J Biol Chem – volume: 87 start-page: 255 year: 2006 end-page: 265 ident: bib21 article-title: Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors publication-title: J Gen Virol – volume: 7 start-page: e688 year: 2020 end-page: e698 ident: bib79 article-title: Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study publication-title: Lancet HIV – volume: 36 start-page: 109400 year: 2021 ident: bib43 article-title: A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters publication-title: Cell Rep – volume: 10 start-page: 1349 year: 1999 end-page: 1358 ident: bib69 article-title: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo publication-title: Hum Gene Ther – volume: 8 start-page: 1456 year: 2017 ident: bib49 article-title: T helper 17 promotes induction of antigen-specific gut-mucosal cytotoxic T lymphocytes following adenovirus vector vaccination publication-title: Front Immunol – volume: 19 start-page: 133 year: 2008 end-page: 142 ident: bib19 article-title: Downregulation of CD46 during muscle differentiation: implications for gene transfer to human skeletal muscle using group B adenoviruses publication-title: Hum Gene Ther – start-page: 218 year: 2021 ident: bib48 article-title: Mapping and role of T cell response in SARS-CoV-2-infected mice publication-title: J Exp Med – volume: 17 start-page: 96 year: 2011 end-page: 104 ident: bib10 article-title: Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 publication-title: Nat Med – volume: 395 start-page: 1845 year: 2020 end-page: 1854 ident: bib106 article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial publication-title: Lancet (Lond. Engl.) – volume: 384 start-page: 2092 year: 2021 end-page: 2101 ident: bib101 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination publication-title: N Engl J Med – volume: 96 start-page: 2734 year: 2015 end-page: 2742 ident: bib1 article-title: Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient publication-title: J Gen Virol – volume: 8 start-page: 1300 year: 2006 end-page: 1306 ident: bib25 article-title: Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production publication-title: J Gene Med – volume: 84 start-page: 5986 year: 2010 end-page: 5996 ident: bib47 article-title: Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes publication-title: J Virol – volume: 83 start-page: 9584 year: 2009 end-page: 9590 ident: bib61 article-title: Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys publication-title: J Virol – volume: 586 start-page: 583 year: 2020 end-page: 588 ident: bib104 article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques publication-title: Nature – volume: 9 start-page: 441 year: 2015 end-page: 455 ident: bib90 article-title: Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives publication-title: J Infect Dev Ctries – volume: 125 start-page: 1129 year: 2015 end-page: 1146 ident: bib45 article-title: Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling publication-title: J Clin Invest – volume: 199 start-page: 3293 year: 2017 end-page: 3305 ident: bib39 article-title: Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS/IFI16-STING-type I IFN pathway and AIM2 sensor publication-title: J Immunol – volume: 396 start-page: 887 year: 2020 end-page: 897 ident: bib105 article-title: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia publication-title: Lancet (Lond. Engl.) – volume: 5 start-page: 357 year: 2010 end-page: 361 ident: bib78 article-title: Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine publication-title: Curr Opin HIV AIDS – volume: 174 start-page: 7179 year: 2005 end-page: 7185 ident: bib52 article-title: Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein publication-title: J Immunol – year: 2021 ident: bib74 article-title: Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles publication-title: Mol Ther – volume: 9 start-page: 124 year: 2018 ident: bib38 article-title: Humoral responses elicited by adenovirus displaying epitopes are induced independently of the infection process and shaped by the toll-like receptor/MyD88 pathway publication-title: Front Immunol – volume: 9 start-page: 221 year: 2020 end-page: 236 ident: bib95 article-title: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan publication-title: Emerg Microb Infect – volume: 81 start-page: 4654 year: 2007 end-page: 4663 ident: bib54 article-title: Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D publication-title: J Virol – volume: 211 start-page: 518 year: 2015 end-page: 528 ident: bib41 article-title: Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans publication-title: J Infect Dis – volume: 23 start-page: 1029 year: 2005 end-page: 1036 ident: bib87 article-title: Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans publication-title: Vaccine – volume: 70 start-page: 6839 year: 1996 end-page: 6846 ident: bib15 article-title: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism publication-title: J Virol – volume: 98 start-page: 15191 year: 2001 end-page: 15196 ident: bib3 article-title: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction publication-title: Proc Natl Acad Sci U S A – volume: 132 start-page: 397 year: 2008 end-page: 409 ident: bib6 article-title: Adenovirus serotype 5 hexon mediates liver gene transfer publication-title: Cell – volume: 275 start-page: 1320 year: 1997 end-page: 1323 ident: bib2 article-title: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 publication-title: Science – volume: 5 start-page: 233 year: 2002 end-page: 241 ident: bib71 article-title: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses publication-title: Mol Ther – volume: 397 start-page: 671 year: 2021 end-page: 681 ident: bib97 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet (Lond. Engl.) – volume: 89 start-page: 56 year: 2016 end-page: 66 ident: bib73 article-title: Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy publication-title: Biomaterials – volume: 8 start-page: 813 year: 2003 end-page: 821 ident: bib7 article-title: Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector publication-title: Mol Ther – volume: 74 start-page: 313 year: 2006 end-page: 320 ident: bib57 article-title: Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice publication-title: Infect Immun – volume: 268 start-page: 1 year: 2019 end-page: 10 ident: bib66 article-title: A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development publication-title: Virus Res – volume: 122 year: 2021 ident: bib102 article-title: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines publication-title: J Autoimmun – volume: 452 start-page: 103 year: 2008 end-page: 107 ident: bib40 article-title: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response publication-title: Nature – volume: 90 start-page: 5915 year: 2016 end-page: 5927 ident: bib33 article-title: Diminished innate antiviral response to adenovirus vectors in cGAS/STING-deficient mice minimally impacts adaptive immunity publication-title: J Virol – volume: 18 start-page: 539 year: 2021 end-page: 555 ident: bib34 article-title: Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors publication-title: Cell Mol Immunol – volume: 385 start-page: 2272 year: 2015 end-page: 2279 ident: bib94 article-title: Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial publication-title: Lancet (Lond. Engl.) – volume: 181 start-page: 4188 year: 2008 end-page: 4198 ident: bib50 article-title: Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination publication-title: J Immunol – volume: 72 start-page: 6875 year: 1998 end-page: 6879 ident: bib58 article-title: Circumvention of immunity to the adenovirus major coat protein hexon publication-title: J Virol – volume: 7 year: 2012 ident: bib65 article-title: A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity publication-title: PLoS One – volume: 160 start-page: 300 year: 1995 end-page: 304 ident: bib89 article-title: Adenovirus vaccines in the U.S. military publication-title: Mil Med – volume: 20 start-page: 1126 year: 2014 end-page: 1129 ident: bib93 article-title: Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge publication-title: Nat Med – year: 2020 ident: bib103 article-title: ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques publication-title: BioRxiv Prepr Serv Biol – volume: 84 start-page: 630 year: 2010 end-page: 638 ident: bib59 article-title: Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization publication-title: J Virol – volume: 29 start-page: 146 year: 2018 end-page: 154 ident: bib86 article-title: Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults publication-title: EBioMedicine – volume: 13 start-page: 17 year: 2011 end-page: 25 ident: bib62 article-title: Creation of a panel of vectors based on ape adenovirus isolates publication-title: J Gene Med – volume: 396 start-page: 479 year: 2020 end-page: 488 ident: bib99 article-title: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet (Lond. Engl.) – volume: 39 start-page: 601 year: 2003 end-page: 609 ident: bib70 article-title: Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines publication-title: Oral Oncol – volume: 79 start-page: 341 year: 1993 end-page: 347 ident: bib20 article-title: Identification and quantification of complement regulator CD46 on normal human tissues publication-title: Immunology – volume: 1 start-page: 569 year: 1977 end-page: 571 ident: bib91 article-title: Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire publication-title: Lancet (Lond. Engl.) – volume: 425 start-page: 89 year: 2012 end-page: 93 ident: bib37 article-title: Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa publication-title: Biochem Biophys Res Commun – volume: 395 start-page: 182 year: 2009 end-page: 189 ident: bib42 article-title: Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge publication-title: Virology – volume: 74 start-page: 42 year: 2000 end-page: 48 ident: bib11 article-title: Adenovirus type 37 uses sialic acid as a cellular receptor publication-title: J Virol – volume: 84 start-page: 10522 year: 2010 end-page: 10532 ident: bib17 article-title: Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae publication-title: J Virol – volume: 85 start-page: 4035 year: 2011 end-page: 4040 ident: bib36 article-title: Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway publication-title: J Virol – volume: 372 start-page: 1881 year: 2008 end-page: 1893 ident: bib76 article-title: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial publication-title: Lancet (Lond. Engl.) – volume: 39 start-page: 3067 year: 2021 end-page: 3080 ident: bib92 article-title: The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform publication-title: Vaccine – volume: 87 start-page: 2891 year: 2006 end-page: 2899 ident: bib55 article-title: Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity publication-title: J Gen Virol – volume: 18 start-page: 753 year: 2007 end-page: 762 ident: bib27 article-title: Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors publication-title: Hum Gene Ther – volume: 9 start-page: 1408 year: 2003 end-page: 1412 ident: bib8 article-title: CD46 is a cellular receptor for group B adenoviruses publication-title: Nat Med – volume: 78 start-page: 13207 year: 2004 end-page: 13215 ident: bib51 article-title: Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5 publication-title: J Virol – volume: 75 start-page: 11603 year: 2001 end-page: 11613 ident: bib64 article-title: Replication-defective vector based on a chimpanzee adenovirus publication-title: J Virol – volume: 73 start-page: 309 year: 1993 end-page: 319 ident: bib4 article-title: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment publication-title: Cell – volume: 77 start-page: 9183 year: 2003 end-page: 9191 ident: bib9 article-title: Adenovirus type 11 uses CD46 as a cellular receptor publication-title: J Virol – volume: 19 start-page: 629 year: 2012 end-page: 637 ident: bib44 article-title: Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route publication-title: Clin Vaccine Immunol – start-page: 131 year: 2021 ident: bib88 article-title: A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity publication-title: J Clin Invest – volume: 85 start-page: 315 year: 2011 end-page: 323 ident: bib31 article-title: Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors publication-title: J Virol – volume: 372 start-page: 1881 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib76 article-title: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(08)61591-3 – volume: 586 start-page: 583 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib104 article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-2607-z – volume: 498 start-page: 380 year: 2013 ident: 10.1016/j.dmpk.2021.100432_bib32 article-title: cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING publication-title: Nature doi: 10.1038/nature12306 – volume: 441 start-page: 239 year: 2006 ident: 10.1016/j.dmpk.2021.100432_bib60 article-title: Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity publication-title: Nature doi: 10.1038/nature04721 – year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib74 article-title: Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles publication-title: Mol Ther doi: 10.1016/j.ymthe.2021.05.015 – volume: 371 start-page: 521 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib46 article-title: MAIT cell activation augments adenovirus vector vaccine immunogenicity publication-title: Science doi: 10.1126/science.aax8819 – volume: 7 start-page: e688 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib79 article-title: Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study publication-title: Lancet HIV doi: 10.1016/S2352-3018(20)30229-0 – volume: 372 start-page: 1894 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib77 article-title: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(08)61592-5 – volume: 20 start-page: 1126 year: 2014 ident: 10.1016/j.dmpk.2021.100432_bib93 article-title: Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge publication-title: Nat Med doi: 10.1038/nm.3702 – volume: 18 start-page: 539 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib34 article-title: Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-00602-7 – volume: 8 start-page: 1456 year: 2017 ident: 10.1016/j.dmpk.2021.100432_bib49 article-title: T helper 17 promotes induction of antigen-specific gut-mucosal cytotoxic T lymphocytes following adenovirus vector vaccination publication-title: Front Immunol doi: 10.3389/fimmu.2017.01456 – volume: 39 start-page: 3067 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib92 article-title: The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform publication-title: Vaccine doi: 10.1016/j.vaccine.2020.08.050 – volume: 5 start-page: 233 year: 2002 ident: 10.1016/j.dmpk.2021.100432_bib71 article-title: Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses publication-title: Mol Ther doi: 10.1006/mthe.2002.0545 – volume: 396 start-page: 479 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib99 article-title: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(20)31605-6 – volume: 397 start-page: 1351 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib96 article-title: Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(21)00628-0 – volume: 593 start-page: 3461 year: 2019 ident: 10.1016/j.dmpk.2021.100432_bib24 article-title: Innate immunity to adenovirus: lessons from mice publication-title: FEBS Lett doi: 10.1002/1873-3468.13696 – volume: 174 start-page: 585 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib84 article-title: A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an ad26-vectored anti-zika virus vaccine publication-title: Ann Intern Med doi: 10.7326/M20-5306 – volume: 396 start-page: 887 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib105 article-title: Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(20)31866-3 – volume: 10 start-page: 1041 year: 2003 ident: 10.1016/j.dmpk.2021.100432_bib14 article-title: Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector publication-title: Gene Ther doi: 10.1038/sj.gt.3301959 – volume: 70 start-page: 6839 year: 1996 ident: 10.1016/j.dmpk.2021.100432_bib15 article-title: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism publication-title: J Virol doi: 10.1128/jvi.70.10.6839-6846.1996 – volume: 73 start-page: 309 year: 1993 ident: 10.1016/j.dmpk.2021.100432_bib4 article-title: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment publication-title: Cell doi: 10.1016/0092-8674(93)90231-E – volume: 78 start-page: 13207 year: 2004 ident: 10.1016/j.dmpk.2021.100432_bib51 article-title: Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5 publication-title: J Virol doi: 10.1128/JVI.78.23.13207-13215.2004 – volume: 74 start-page: 313 year: 2006 ident: 10.1016/j.dmpk.2021.100432_bib57 article-title: Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice publication-title: Infect Immun doi: 10.1128/IAI.74.1.313-320.2006 – volume: 81 start-page: 4654 year: 2007 ident: 10.1016/j.dmpk.2021.100432_bib54 article-title: Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D publication-title: J Virol doi: 10.1128/JVI.02696-06 – volume: 19 start-page: 133 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib19 article-title: Downregulation of CD46 during muscle differentiation: implications for gene transfer to human skeletal muscle using group B adenoviruses publication-title: Hum Gene Ther doi: 10.1089/hum.2007.040 – volume: 395 start-page: 182 year: 2009 ident: 10.1016/j.dmpk.2021.100432_bib42 article-title: Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge publication-title: Virology doi: 10.1016/j.virol.2009.09.018 – volume: 23 start-page: 1029 year: 2005 ident: 10.1016/j.dmpk.2021.100432_bib87 article-title: Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans publication-title: Vaccine doi: 10.1016/j.vaccine.2004.07.043 – volume: 39 start-page: 601 year: 2003 ident: 10.1016/j.dmpk.2021.100432_bib70 article-title: Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines publication-title: Oral Oncol doi: 10.1016/S1368-8375(03)00047-2 – volume: 274 start-page: 10219 year: 1999 ident: 10.1016/j.dmpk.2021.100432_bib22 article-title: Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia publication-title: J Biol Chem doi: 10.1074/jbc.274.15.10219 – volume: 19 start-page: 629 year: 2012 ident: 10.1016/j.dmpk.2021.100432_bib44 article-title: Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00010-12 – volume: 181 start-page: 2134 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib28 article-title: Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo publication-title: J Immunol doi: 10.4049/jimmunol.181.3.2134 – volume: 32 start-page: 1724 year: 2011 ident: 10.1016/j.dmpk.2021.100432_bib68 article-title: Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.10.060 – volume: 17 start-page: 96 year: 2011 ident: 10.1016/j.dmpk.2021.100432_bib10 article-title: Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 publication-title: Nat Med doi: 10.1038/nm.2270 – volume: 452 start-page: 103 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib40 article-title: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response publication-title: Nature doi: 10.1038/nature06664 – volume: 79 start-page: 341 year: 1993 ident: 10.1016/j.dmpk.2021.100432_bib20 article-title: Identification and quantification of complement regulator CD46 on normal human tissues publication-title: Immunology – start-page: 218 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib48 article-title: Mapping and role of T cell response in SARS-CoV-2-infected mice publication-title: J Exp Med – volume: 9 start-page: 221 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib95 article-title: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan publication-title: Emerg Microb Infect doi: 10.1080/22221751.2020.1719902 – volume: 18 start-page: 753 year: 2007 ident: 10.1016/j.dmpk.2021.100432_bib27 article-title: Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors publication-title: Hum Gene Ther doi: 10.1089/hum.2007.016 – volume: 72 start-page: 6875 year: 1998 ident: 10.1016/j.dmpk.2021.100432_bib58 article-title: Circumvention of immunity to the adenovirus major coat protein hexon publication-title: J Virol doi: 10.1128/JVI.72.8.6875-6879.1998 – volume: 75 start-page: 11603 year: 2001 ident: 10.1016/j.dmpk.2021.100432_bib64 article-title: Replication-defective vector based on a chimpanzee adenovirus publication-title: J Virol doi: 10.1128/JVI.75.23.11603-11613.2001 – volume: 74 start-page: 2567 year: 2000 ident: 10.1016/j.dmpk.2021.100432_bib13 article-title: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector publication-title: J Virol doi: 10.1128/JVI.74.6.2567-2583.2000 – volume: 9 start-page: 124 year: 2018 ident: 10.1016/j.dmpk.2021.100432_bib38 article-title: Humoral responses elicited by adenovirus displaying epitopes are induced independently of the infection process and shaped by the toll-like receptor/MyD88 pathway publication-title: Front Immunol doi: 10.3389/fimmu.2018.00124 – volume: 199 start-page: 3293 year: 2017 ident: 10.1016/j.dmpk.2021.100432_bib39 article-title: Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS/IFI16-STING-type I IFN pathway and AIM2 sensor publication-title: J Immunol doi: 10.4049/jimmunol.1700698 – volume: 5 start-page: 2569 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib100 article-title: A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 publication-title: Blood Adv doi: 10.1182/bloodadvances.2021004904 – volume: 1 start-page: 569 year: 1977 ident: 10.1016/j.dmpk.2021.100432_bib91 article-title: Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(77)92000-1 – volume: 13 start-page: 17 year: 2011 ident: 10.1016/j.dmpk.2021.100432_bib62 article-title: Creation of a panel of vectors based on ape adenovirus isolates publication-title: J Gene Med doi: 10.1002/jgm.1530 – volume: 8 start-page: 1300 year: 2006 ident: 10.1016/j.dmpk.2021.100432_bib25 article-title: Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production publication-title: J Gene Med doi: 10.1002/jgm.964 – volume: 5 start-page: 357 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib78 article-title: Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e32833d2d2b – volume: 74 start-page: 42 year: 2000 ident: 10.1016/j.dmpk.2021.100432_bib11 article-title: Adenovirus type 37 uses sialic acid as a cellular receptor publication-title: J Virol doi: 10.1128/JVI.74.1.42-48.2000 – volume: 62 start-page: 145 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib85 article-title: Influenza vaccine for 2020-2021 publication-title: Med Lett Drugs Ther – volume: 8 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib75 article-title: Extracellular vesicles-mimetic encapsulation improves oncolytic viro-immunotherapy in tumors with low coxsackie and adenovirus receptor publication-title: Front Bioeng Biotechnol doi: 10.3389/fbioe.2020.574007 – volume: 92 year: 2018 ident: 10.1016/j.dmpk.2021.100432_bib82 article-title: Recombinant chimpanzee adenovirus vaccine AdC7-M/E protects against Zika virus infection and testis damage publication-title: J Virol doi: 10.1128/JVI.01722-17 – volume: 384 start-page: 2092 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib101 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination publication-title: N Engl J Med doi: 10.1056/NEJMoa2104840 – volume: 98 start-page: 15191 year: 2001 ident: 10.1016/j.dmpk.2021.100432_bib3 article-title: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.261452898 – volume: 77 start-page: 9183 year: 2003 ident: 10.1016/j.dmpk.2021.100432_bib9 article-title: Adenovirus type 11 uses CD46 as a cellular receptor publication-title: J Virol doi: 10.1128/JVI.77.17.9183-9191.2003 – volume: 387 start-page: 335 year: 2016 ident: 10.1016/j.dmpk.2021.100432_bib81 article-title: Anticipating the international spread of Zika virus from Brazil publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(16)00080-5 – volume: 8 start-page: 813 year: 2003 ident: 10.1016/j.dmpk.2021.100432_bib7 article-title: Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector publication-title: Mol Ther doi: 10.1016/S1525-0016(03)00243-0 – volume: 84 start-page: 630 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib59 article-title: Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization publication-title: J Virol doi: 10.1128/JVI.00866-09 – volume: 96 start-page: 2734 year: 2015 ident: 10.1016/j.dmpk.2021.100432_bib1 article-title: Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient publication-title: J Gen Virol doi: 10.1099/vir.0.000196 – volume: 122 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib102 article-title: Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines publication-title: J Autoimmun doi: 10.1016/j.jaut.2021.102681 – volume: 425 start-page: 89 year: 2012 ident: 10.1016/j.dmpk.2021.100432_bib37 article-title: Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2012.07.056 – volume: 107 start-page: 17286 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib35 article-title: Induction of type I interferon by adenovirus-encoded small RNAs publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1009823107 – volume: 268 start-page: 1 year: 2019 ident: 10.1016/j.dmpk.2021.100432_bib66 article-title: A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development publication-title: Virus Res doi: 10.1016/j.virusres.2019.05.008 – volume: 275 start-page: 1320 year: 1997 ident: 10.1016/j.dmpk.2021.100432_bib2 article-title: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 publication-title: Science doi: 10.1126/science.275.5304.1320 – volume: 181 start-page: 4188 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib50 article-title: Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination publication-title: J Immunol doi: 10.4049/jimmunol.181.6.4188 – volume: 9 start-page: 441 year: 2015 ident: 10.1016/j.dmpk.2021.100432_bib90 article-title: Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives publication-title: J Infect Dev Ctries doi: 10.3855/jidc.6197 – volume: 83 start-page: 9584 year: 2009 ident: 10.1016/j.dmpk.2021.100432_bib61 article-title: Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys publication-title: J Virol doi: 10.1128/JVI.00821-09 – volume: 16 start-page: 5998 year: 1997 ident: 10.1016/j.dmpk.2021.100432_bib5 article-title: The role of the nuclear pore complex in adenovirus DNA entry publication-title: EMBO J doi: 10.1093/emboj/16.19.5998 – volume: 385 start-page: 2272 year: 2015 ident: 10.1016/j.dmpk.2021.100432_bib94 article-title: Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(15)60553-0 – volume: 384 start-page: 2187 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib98 article-title: Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 – volume: 7 start-page: 105 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib72 article-title: Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells publication-title: Mol Pharm doi: 10.1021/mp900151k – start-page: 131 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib88 article-title: A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity publication-title: J Clin Invest – volume: 395 start-page: 1845 year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib106 article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(20)31208-3 – volume: 90 start-page: 5915 year: 2016 ident: 10.1016/j.dmpk.2021.100432_bib33 article-title: Diminished innate antiviral response to adenovirus vectors in cGAS/STING-deficient mice minimally impacts adaptive immunity publication-title: J Virol doi: 10.1128/JVI.00500-16 – volume: 107 start-page: 19985 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib56 article-title: Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1014074107 – volume: 89 start-page: 56 year: 2016 ident: 10.1016/j.dmpk.2021.100432_bib73 article-title: Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy publication-title: Biomaterials doi: 10.1016/j.biomaterials.2016.02.025 – year: 2020 ident: 10.1016/j.dmpk.2021.100432_bib103 article-title: ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques publication-title: BioRxiv Prepr Serv Biol – volume: 85 start-page: 315 year: 2011 ident: 10.1016/j.dmpk.2021.100432_bib31 article-title: Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors publication-title: J Virol doi: 10.1128/JVI.01597-10 – volume: 272 start-page: 20793 year: 1997 ident: 10.1016/j.dmpk.2021.100432_bib23 article-title: Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed. Importance of the tetrapeptide FTSL at the carboxyl terminus publication-title: J Biol Chem doi: 10.1074/jbc.272.33.20793 – volume: 10 start-page: 1349 year: 1999 ident: 10.1016/j.dmpk.2021.100432_bib69 article-title: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo publication-title: Hum Gene Ther doi: 10.1089/10430349950018021 – volume: 10 start-page: 1009 year: 1999 ident: 10.1016/j.dmpk.2021.100432_bib18 article-title: Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells publication-title: Hum Gene Ther doi: 10.1089/10430349950018409 – volume: 160 start-page: 300 year: 1995 ident: 10.1016/j.dmpk.2021.100432_bib89 article-title: Adenovirus vaccines in the U.S. military publication-title: Mil Med doi: 10.1093/milmed/160.6.300 – volume: 132 start-page: 397 year: 2008 ident: 10.1016/j.dmpk.2021.100432_bib6 article-title: Adenovirus serotype 5 hexon mediates liver gene transfer publication-title: Cell doi: 10.1016/j.cell.2008.01.016 – volume: 5 start-page: eaax3567 year: 2019 ident: 10.1016/j.dmpk.2021.100432_bib12 article-title: Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor publication-title: Sci Adv doi: 10.1126/sciadv.aax3567 – volume: 12 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib30 article-title: Lactoferrin retargets human adenoviruses to TLR4 to induce an abortive NLRP3-associated pyroptotic response in human phagocytes publication-title: Front Immunol doi: 10.3389/fimmu.2021.685218 – volume: 7 year: 2012 ident: 10.1016/j.dmpk.2021.100432_bib65 article-title: A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity publication-title: PLoS One doi: 10.1371/journal.pone.0040385 – volume: 9 year: 2014 ident: 10.1016/j.dmpk.2021.100432_bib80 article-title: Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial publication-title: PLoS One doi: 10.1371/journal.pone.0101591 – volume: 84 start-page: 10522 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib17 article-title: Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae publication-title: J Virol doi: 10.1128/JVI.00450-10 – volume: 397 start-page: 671 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib97 article-title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia publication-title: Lancet (Lond. Engl.) doi: 10.1016/S0140-6736(21)00234-8 – volume: 29 start-page: 146 year: 2018 ident: 10.1016/j.dmpk.2021.100432_bib86 article-title: Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults publication-title: EBioMedicine doi: 10.1016/j.ebiom.2018.02.011 – volume: 9 start-page: 1408 year: 2003 ident: 10.1016/j.dmpk.2021.100432_bib8 article-title: CD46 is a cellular receptor for group B adenoviruses publication-title: Nat Med doi: 10.1038/nm952 – volume: 218 start-page: 365 year: 2018 ident: 10.1016/j.dmpk.2021.100432_bib83 article-title: Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models publication-title: J Infect Dis doi: 10.1093/infdis/jiy187 – volume: 1 start-page: 376 year: 2009 ident: 10.1016/j.dmpk.2021.100432_bib29 article-title: TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses publication-title: J Innate Immun – volume: 174 start-page: 7179 year: 2005 ident: 10.1016/j.dmpk.2021.100432_bib52 article-title: Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein publication-title: J Immunol doi: 10.4049/jimmunol.174.11.7179 – volume: 15 start-page: 378 year: 2007 ident: 10.1016/j.dmpk.2021.100432_bib26 article-title: Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors publication-title: Mol Ther doi: 10.1038/sj.mt.6300031 – volume: 211 start-page: 518 year: 2015 ident: 10.1016/j.dmpk.2021.100432_bib41 article-title: Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans publication-title: J Infect Dis doi: 10.1093/infdis/jiu485 – volume: 36 start-page: 109400 year: 2021 ident: 10.1016/j.dmpk.2021.100432_bib43 article-title: A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109400 – volume: 8 start-page: 2103 year: 1997 ident: 10.1016/j.dmpk.2021.100432_bib63 article-title: A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo publication-title: Hum Gene Ther doi: 10.1089/hum.1997.8.17-2103 – volume: 33 start-page: 3743 year: 2012 ident: 10.1016/j.dmpk.2021.100432_bib67 article-title: A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X publication-title: Biomaterials doi: 10.1016/j.biomaterials.2012.02.011 – volume: 87 start-page: 2891 year: 2006 ident: 10.1016/j.dmpk.2021.100432_bib55 article-title: Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity publication-title: J Gen Virol doi: 10.1099/vir.0.82079-0 – volume: 87 start-page: 255 year: 2006 ident: 10.1016/j.dmpk.2021.100432_bib21 article-title: Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors publication-title: J Gen Virol doi: 10.1099/vir.0.81293-0 – volume: 85 start-page: 4035 year: 2011 ident: 10.1016/j.dmpk.2021.100432_bib36 article-title: Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway publication-title: J Virol doi: 10.1128/JVI.02160-10 – volume: 125 start-page: 1129 year: 2015 ident: 10.1016/j.dmpk.2021.100432_bib45 article-title: Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling publication-title: J Clin Invest doi: 10.1172/JCI78280 – volume: 84 start-page: 5986 year: 2010 ident: 10.1016/j.dmpk.2021.100432_bib47 article-title: Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes publication-title: J Virol doi: 10.1128/JVI.02563-09 – volume: 11 start-page: 351 year: 2004 ident: 10.1016/j.dmpk.2021.100432_bib53 article-title: Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States publication-title: Clin Diagn Lab Immunol – volume: 79 start-page: 5090 year: 2005 ident: 10.1016/j.dmpk.2021.100432_bib16 article-title: Development and assessment of human adenovirus type 11 as a gene transfer vector publication-title: J Virol doi: 10.1128/JVI.79.8.5090-5104.2005 |
| SSID | ssj0033542 |
| Score | 2.5573745 |
| SecondaryResourceType | review_article |
| Snippet | Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 100432 |
| SubjectTerms | Adenoviridae - genetics Adenovirus Vaccines Adenovirus vector Communicable Diseases COVID-19 Genetic Vectors - genetics Humans Infectious diseases Innate immunity Pre-existing antibody Review SARS-CoV-2 Vaccine Vaccines |
| Title | Adenovirus vector-based vaccine for infectious diseases |
| URI | https://dx.doi.org/10.1016/j.dmpk.2021.100432 https://www.ncbi.nlm.nih.gov/pubmed/34974335 https://www.proquest.com/docview/2616278679 https://pubmed.ncbi.nlm.nih.gov/PMC8585960 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7Bcumlgj63FORKFZdibRzbsXNcIei2VRFSQdqblfihLm3DioWV-Pf1JM7CtiqHXpOxZM1M5pGZ-QbgvZa-dqouqeaioqLwNdUhV5TpupSOsWAFDjh_PS0mF-LzVE434KifhcG2ymT7O5veWuv0ZJS4OZrPZqNvOAQpeBFTmA6VZBO28uhdswFsjT99mZz2Bplz2e7QQXqKB9LsTNfm5X7Nf8Q0MWfYLyB4_i__9Hf8-Wcb5QO_dLINT1NAScbdnXdgwzfP4OCsQ6S-OyTn9wNWi0NyQM7usarvnoMaR7tztZxd3y7Isv2BT9GvObKsLJbcSYxpSd-wFWlSPWfxAi5Ojs-PJjTtUqAWVxZQDHOsLrwsbbQoLis9k3VMjJW1QmUyBM6tEjpzqlJlpXXwzumgNa4BFj5Y_hIGzVXjXwPJQuF1bq2WrhQFq2rhc8aroo65XRCVGALrOWhsAhrHfRc_Td9RdmmQ6wa5bjquD-HD6sy8g9l4lFr2gjFrymKiH3j03LteiiZ-RVgaqRofuWdiHlnkCsEHh_Cqk-rqHlzEnCsq0RDUmrxXBIjQvf6mmX1vkbqx6BpTxDf_ed9deJLjtEXbJP4WBjfXt34vxkA39X7S8X3Y_DhlvwGtkAY7 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6V9gAXxJvwXCTohVqJvWvv-sAhAqqEtFElUqm3xd6HCC1u1LRB-V38QWbsdUpA9IDUq722RjM7L83MNwCvVepKK8s8UlwUkchcGSmfyChWZZ7aOPZG0IDz_jgbHIpPR-nRBvxsZ2GorTLY_sam19Y6POkGbnZn02n3Mw1BCp5hCtOgkoTOypFb_sC8bf5u-AGF_CZJdj9O3g-isFogMoTgH5HXNypzaW5QwWwvd3FaYp4ojRGyl3rPuZFC9awsZF4o5Z21yitFW3GF84bjf2_AFqFhoVpt9Yejwbh1AJyn9c4eoi8iAsOsTtNWZr_PjjEtTWLqTxA8-Zc__Dve_bNt8zc_uHsHbocAlvUbHt2FDVfdg-2DBgF7ucMmlwNd8x22zQ4usbGX90H20c6dLqZnF3O2qAsGEflRyxaFoRI_wxiatQ1ieCbUj-YP4PBaGPwQNqvTyj0G1vOZU4kxKrW5yOKiFC6JeZGVmEt6UYgOxC0HtQnA5rRf40S3HWzfNHFdE9d1w_UOvF19M2tgPa48nbaC0WuXU6PfufK7V60UNWotlWKKyiH3NOatWSIJ7LADjxqprujgAnM8vEQdkGvyXh0gRPD1N9X0a40MTkVeTEmf_Ce9L-HmYLK_p_eG49FTuJXQpEfdoP4MNs_PLtxzjL_OyxfhvjP4ct0q9gvWLUGl |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adenovirus+vector-based+vaccine+for+infectious+diseases&rft.jtitle=Drug+metabolism+and+pharmacokinetics&rft.au=Sakurai%2C+Fuminori&rft.au=Tachibana%2C+Masashi&rft.au=Mizuguchi%2C+Hiroyuki&rft.date=2022-02-01&rft.eissn=1880-0920&rft.volume=42&rft.spage=100432&rft_id=info:doi/10.1016%2Fj.dmpk.2021.100432&rft_id=info%3Apmid%2F34974335&rft.externalDocID=34974335 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-4367&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-4367&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-4367&client=summon |